Delphine Imbert

NetSuite Outlook Greenhouse.io Media Temple SSL WP Engine Adobe Marketing Cloud reCAPTCHA WordPress.org YouTube Google Tag Manager Google Analytics Mobile Friendly Remote AI

fibrosis integrins muscle biology oncology duchenne muscular dystrophy idiopathic pulmonary fibrosis primary sclerosing cholangitis muscular dystrophy metabolic dysfunctionassociated steatohepatitis mash biotechnology: pharmaceutical preparations health care biotechnology research integrin inhibitors clinical trials biopharmaceutical targeted therapies orally available molecular drivers tissue-specific therapies small molecule drugs drug development preclinical studies breakthrough therapies fast track designation orphan drug designation solid tumors pediatric treatments innovative therapeutics biological research patient commitment therapeutic pipeline healthcare investors clinical stage biologics medicinal chemistry molecular biology safety & efficacy drug discovery regulatory affairs healthcare governance sustainable practices advanced therapies therapeutic targets investor relations medical research clinical operations drug formulation patient support healthcare compliance integrin v1 integrin v6 clinical research drug safety biotechnology firms drug regulation education & community outreach scientific leadership fibrotic diseases novel therapies tgf-β modulation oral small-molecule drugs clinical-stage biopharmaceutical tissue-specific treatments patient-centric approach unmet medical needs muscular dystrophies nash-associated liver fibrosis strategic partnerships novartis collaboration research & development regulatory designations phase 1 trials phase 2 trials patient advocacy healthcare providers scientific excellence innovation market research treatment-resistant patients organ dysfunction scar tissue growth therapeutic focus hospital & health care health wellness & fitness